Background: Lactation failing is one of the leads to infants weight loss and illness. Vary degree of success have been reported with many strategies to increase milk production when it is failed. This study was investigated the effect of DOMPERIDONE in augmentation milk production Methods and Material: In a double blind placebo controlled trial 48 mothers that their infants were under grow square and it was due to mothers milk not enough, randomly divided to two groups: 24 received DOMPERIDONE 10mg TDS orally for 14 days and 24 received placebo (the same shape) TDS orally for 14 days. Milk volume was measured the day before study on day 7, 14 and one week after study; and serum prolactin level was measured the day before study, day 14 and one week after the study. SPSS 11.5 software was used to analyze the results with Q square test and T student test; and P<0.05 was significantly difference.Results: Data obtained from two group of study indicated treatment with DOMPERIDONE increased the volume of milk amount 48.5 ml compared 8 ml in treatment with placebo.(P=0.008) a+lso serum prolactin was raised 116.4 ng/ml in DOMPERIDONE group compared with 4ng/ml in placebo group (P=0.001).Conclusion: DOMPERIDONE is an effective drug in milk production increasing and serum prolactin.

The purpose of this research was to prepare a floating matrix tablet containing DOMPERIDONE as a model drug. Polyethylene oxide (PEO) and hydroxypropyl methylcellulose (HPMC) were evaluated for matrix-forming properties. A simplex lattice design was applied to systemically optimize the drug release profile. The amounts of PEO WSR 303, HPMC K15M and sodium bicarbonate were selected as independent variables and floating lag time, time required to release 50% of drug (t50) and 80% of drug (t80), diffusion coefficient (n) and release rate (k) as dependent variables. The amount of PEO and HPMC both had significant influence on the dependent variables. It was found that the content of PEO had dominating role as drug release controlling factor, but using suitable concentration of sodium bicarbonate, one can tailor the desired drug release from hydrophilic matrixes. The linear regression analysis and model fitting showed that all these formulations followed Korsmeyer and Peppas model, which had a higher value of correlation coefficient (r). The tablets of promising formulation were found to be stable for 3 months under accelerated (40oC / 75% RH) stability testing.

DOMPERIDONE is a widely used antiemetic, poorly water soluble drug, erratically absorbed in stomach and possess several dissolution-related problems thus it has poor bioavailability. Solubility of a drug plays a very important role in dissolution and hence absorption of drug which ultimately affects its bioavailability. Hence, by considering the facts related to drug, attempts have been made to formulate inclusion complexes using methylated b-cyclodextrin and also to study the effect of preparation method. Inclusion complexes were prepared using methylated b-cyclodextrin in 1:1 and 1:2 molar ratios. Kneading, ultrasonification and physical mixture method were used for preparation of inclusion complexes. All the inclusion complexes were characterized using FTIR, DSC and XRD. The solubility and dissolution results revealed that there was a considerable increase in solubility and dissolution of all inclusion complexes as compared to pure drug. It was highest in case of methylated b-cyclodextrin in 1:1 molar ratio using ultrasonification method (USM1). Stability study revealed that all complexes were stable for a period of three months.

Background: One of the most common functional problems in children is functional abdominal pain (FAP), and dysmotility is one of the possible causes of FAP. DOMPERIDONE is a prokinetic drug that increases gastrointestinal motility. Objectives: The aim of this study was to evaluate the eff, ect of DOMPERIDONE on the treatment of FAP in children. Methods: In this double-blind clinical trial study, FAP was diagnosed in 80 children aged 5-14 years, who were referred to Amirkola Children’, s Hospital in Babol for one year based on the criteria of the Rome IV. Then, they were randomly divided into two groups of 40 patients. Group A received DOMPERIDONE tablets (0. 25 mg/kg, three-time/day) for two months, and group B received a placebo. The primary outcome was at least a 50% reduction in both frequency and severity of pain, and the secondary outcome was a signifi, cant reduction in the duration, frequency, and intensity of pain according to the Wong-Baker scale compared to baseline. Results: A total of 80 children completed the trial (40 with DOMPERIDONE). The recovery rate was higher in the DOMPERIDONE group than in the placebo group after eight weeks (71. 8% vs. 28. 2%,P < 0. 0001), and DOMPERIDONE had signifi, cant superiority over the placebo in reducing the duration (4. 58 ±,7. 71 vs. 24. 5 ±,41. 45, min/day, P < 0. 001), frequency (3. 35 ±,3. 99 vs. 10. 63 ±,10. 55, episode/week, P < 0. 001), and intensity (2. 20 ±,2. 16 vs. 5. 05 ±,2. 37, P < 0. 001) of the pain. Conclusions: Based on the results, DOMPERIDONE can be useful in the treatment of FAP in children.

Background and the purpose of the study: DOMPERIDONE (DOM) is a dopamine- receptor (D2) antagonist, which is widely used in the treatment of motion-sickness. The pharmacokinetic parameters make DOM a suitable candidate for transdermal delivery. The purpose of the present investigation was to develop transdermal delivery systems for DOM and to evaluate their physicochemical characteristics, in vitro release an ex vivo permeation through rat abdominal skin and their mechanical properties.Methods: Bilayered matrix type transdermal drug delivery systems (TDDS) of DOM were prepared by film casting technique using hydroxypropyl methyl cellulose as primary and Eudragit RL 100 as secondary layers. Brij-35 was incorporated as a solubilizer, d-limonene and propylene glycol were employed as permeation enhancer and plasticizer respectively. The prepared TDDS were extensively evaluated for in vitro release, moisture absorption, moisture content, water vapor transmission, ex vivo permeation through rat abdominal skin, mechanical properties and stability studies. The physicochemical interaction between DOM and polymers were investigated by Differential Scanning Calorimetry (DSC) and Fourier Transform Infrared Spectroscopy (FTIR).Results: All the formulations exhibited satisfactory physicochemical and mechanical characteristics. The optimized formulation F6 showed maximum cumulative percentage of drug release (90.7%), permeation (6806.64 mg) in 24 hrs, flux (86.02 mg /hr/cm2) and permeation coefficient of 0.86x10-2 cm/hr. Values of tensile strength (4.34 kg/mm2) and elastic modulus (5.89 kg/cm2) revealed that formulation F6 was strong but not brittle. DSC and FTIR studies showed no evidence of interaction between the drug and polymers. A shelf life of 2 years is predicted for the TDDS.Conclusions: DOMPERIDONE bilayered matrix type transdermal therapeutic systems could be prepared with the required flux and suitable mechanical properties.

Background and the purpose of the study: DOMPERIDONE (DOM) is a dopamine- receptor (D2) antagonist, widely used in the treatment of motion-sickness. The pharmacokinetic parameters of DOM make it a suitable candidate for development of Solid Lipid Nanoparticle (SLN) and Nanostructured Lipide Carrier (NLC). The purpose of the present investigation was to prepare and evaluate DOM loaded solid lipid nanoparticles (DOM-SLN) and DOM loaded nanostructured lipid carriers (DOM-NLC).Methods: DOM loaded SLN and NLC were prepared by hot homogenization followed by ultrasonication technique, using trimyristin as solid lipid, cetyl recinoleate as liquid lipid and a mixture of soy phosphatidylcholine (99%) and tween 80 as surfactant. SLN and NLC were characterized for particle size, polydispersity index (PDI), zeta potential and entrapment effciency. The effects of composition of lipid materials and surfactant mixture on the particle size, PDI, zeta potential, drug entrapment effciency, and in vitro drug release behavior were investigated. DSC analysis was performed to characterize the state of drug and lipid modifcation. Shape and surface morphology were determined by transmission electron microscopy (TEM). SLN and NLC formulations were subjected to stability study over a period of 40 days.Results: The mean particle size, PDI, zeta potential and entrapment effciency of optimized SLN (SLN1) and NLC were found to be 30.45 nm, 0.156, 12.40 mV, 87.84 % and 32.23 nm, 0.160, 10.47 mV, 90.49 % respectively. DSC studies revealed that DOM was in an amorphous state and triglycerides were in the b prime form in SLN and NLC. Shape and surface morphology was determined by TEM revealed fairly spherical shape of nanoparticles. In vitro release studies demonstrated that both the SLN and NLC formulations possessed a controlled release over a period of 24 hrs. SLN and NLC formulations were subjected to stability over a period of 40 days. There was no signifcant (P<0.05) change in particle size, zeta potential, PDI and entrapment effciency indicating the developed SLN and NLC were fairly stable.Conclusion: Fairly spherical shaped, stable and controlled release DOM-SLN and DOM-NLC could be prepared by hot homogenization followed by ultrasonication technique.

The effectiveness of two kinds of dopamine antagonist (DA), metoclopramide (Met) and DOMPERIDONE (Dom) combined with the gonadotropin releasing hormone analogue (D-Ala6, Des Gly10 ethylamide) GnRHa was assayed on the ovulation success, latency period, ovulation index (OI) and fertilization success of kutum, Rutilus frisii kutum (Kamenskii, 1901). Brood fish were injected intra-peritoneally as follows: 2 mg/kg b.w. of carp pituitary extract (CPE) as a control, 5 g+ 2.5mg, 1mg+ 5mg and 2mg+ 10mg/kg b.w. of GnRHa + Met or Dom in a single injection.Based on the ovulation and fertilization success, no significant differences between similar doses of Dom and Met when combined with similar doses of GnRHa were found (P>0.05). However, in some groups, the OI and latency period were greater when Dom was used as a DA instead of Met (P<0.05). In general, the results of this study showed that the potency of Dom was nearly same as Met when combined with GnRHa and used as a DA in kutum. It is strongly recommended to repeat the experiment under different conditions to find out definite conclusion.

The purpose of the present research was to evaluate the radiographic effect of DOMPERIDONE on the time of passage of the contrast media through the dog's digestive tract. This study was conducted on 15 healthy dogs and in 3 equal groups. The first group received only ketamine and acepromazine drugs, before administration of contrast media. The second and third groups received DOMPERIDONE with dosages (0.1 and 0.5 mg/kg) respectively. Then radiography followed at times zero, 20, 40 and 60 minutes and every one hour until the contrast media reaches the colon. Examining the time of contrast media emptying from the stomach showed that there was difference between the DOMPERIDONE (0.5 mg/kg) group and the groups DOMPERIDONE 0.1 and control had a significant difference (P<0.05). The average time of complete gastric emptying of the contrast media in dogs of control group, DOMPERIDONE groups (0.1 and 0.5 mg/kg) were 96±32.86, 52±10.95 and 48±10.95 minutes, respectively. Significant difference was observed between the control group and the other two groups (P<0.05). The average time for the contrast to reach the colon in dogs of the control group, DOMPERIDONE groups (0.1 and 0.5 mg/kg), 10.2±7.73, 8.2±8.84 and 4.4±1.34 hours, respectively. A significant difference was seen between the DOMPERIDONE (0.5 mg/kg) group against DOMPERIDONE (0.1) groups and control (P<0.05). The results showed that the administration of DOMPERIDONE compared to the control group in both dosage caused complete emptying of the contrast media from the stomach and decreased the time of the contrast media reaching to colon.

The effectiveness of the first Iranian made gonadotropin releasing hormone analogue, [D-Ala6 des-Gly10] GnRH ethylamide, alone or in combination with DOMPERIDONE, a dopamine antagonist on spawning rate, latency period, working fecundity and embryo viability in common carp, Cyprinus carpio, was investigated. Fifty two fish were divided into 5 groups and treated intrapretoneally as follows: 3 mg/Kg b.w. of carp pituitary extract (C.P.E.) as a positive control, GnRHa alone, 10 µg/Kg b.w.. or in combination with DOMPERIDONE, 5 mg/Kg b.w. in a single or double injections 7h apart. A group was treated with propylene glycol 0.2 ml/Kg b.w. alone and considered as control. No female ovulated in groups receiving either propylene glycol or 10 µg/Kg b.w. of GnRHa alone. The spawning rate was higher in female GnRHa+DOMPERIDONE (10 µg/Kg b.w..+5 mg/Kg) in double injections (11 out of 12) as compared to fish which injected either with C.P.E (7 out of 16) or GnRHa + DOMPERIDONE in a single injection (3 out of 12)(P<0.05). The mean working fecundity, was significantly higher for fish receiving GnRHa+DOMPERIDONE in single (126214 ± 24315) or double injections (145600 ± 27113) compared to C.P.E treated group (52435 ± 1224) (P<0.05). There were no significant differences for latency period or embryo viability among the groups.